BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24810093)

  • 1. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.
    Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; ; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; deFazio A
    Sci Rep; 2014 May; 4():4669. PubMed ID: 24810093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
    Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
    Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
    Duan Z; Brakora KA; Seiden MV
    Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
    Vaidyanathan A; Sawers L; Gannon AL; Chakravarty P; Scott AL; Bray SE; Ferguson MJ; Smith G
    Br J Cancer; 2016 Aug; 115(4):431-41. PubMed ID: 27415012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
    McCorkle JR; Gorski JW; Liu J; Riggs MB; McDowell AB; Lin N; Wang C; Ueland FR; Kolesar JM
    PLoS One; 2021; 16(8):e0254205. PubMed ID: 34347777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
    Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
    Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Abdelfattah NM; Solayman MH; Elnahass Y; Sabri NA
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):471-477. PubMed ID: 34280009
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
    Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
    Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of (C1236T and C3435T) Polymorphisms of ABCB1 Gene on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.
    Gudur RA; Bhosale SJ; Gudur AK; Kale SR; More AL; Datkhile KD
    Asian Pac J Cancer Prev; 2024 May; 25(5):1567-1577. PubMed ID: 38809628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
    Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
    Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
    Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.
    Eyre R; Harvey I; Stemke-Hale K; Lennard TW; Tyson-Capper A; Meeson AP
    Tumour Biol; 2014 Oct; 35(10):9879-92. PubMed ID: 24993095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
    Meng X; Wang G; Liu P; Hou J; Jin Y; Yu Y; Bai J; Chen F; Sun W; Fu S
    Respirology; 2011 Nov; 16(8):1228-34. PubMed ID: 21883677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
    Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
    Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
    Christie EL; Pattnaik S; Beach J; Copeland A; Rashoo N; Fereday S; Hendley J; Alsop K; Brady SL; Lamb G; Pandey A; deFazio A; Thorne H; Bild A; Bowtell DDL
    Nat Commun; 2019 Mar; 10(1):1295. PubMed ID: 30894541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1.
    Tian S; Zhang M; Chen X; Liu Y; Lou G
    Oncotarget; 2016 Dec; 7(52):87091-87099. PubMed ID: 27893429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The
    Yin B; Lu P; Liang J; Zhang W; Xin M; Pei K; Li Y
    J Int Med Res; 2019 Oct; 47(10):5256-5269. PubMed ID: 31638462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
    Björn N; Jakobsen Falk I; Vergote I; Gréen H
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):277-287. PubMed ID: 29504705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.